Effect of Vitamin E Fortified Whey Drink on Nutritional, Inflammatory and Oxidative Markers in Hemodialysis Patients

NCT ID: NCT02163070

Last Updated: 2015-01-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this interventional study was to evaluate the effect of vitamin E fortified whey drink on nutritional status, inflammatory markers and oxidative stress in hemodialysis patients. 92 hemodialysis patients were selected for the study. Inclusion criteria included: mean age of 17-65 years old; having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment; being dialyzed at least 2 times a week for 3 months. Exclusion criteria included: hospitalization in the last month; active infection; using immunosuppressant drugs or multi-vitamins; pregnancy. The Ethics Committee of Shiraz University of Medical Sciences reviewed and approved the protocol of this study.Informed consent were signed by all of them for participating in the study. Weight and height of the patients were recorded for BMI (body mass index) calculation. Then, all of the patients were assigned into 4 groups:

1. consumption of 220 milliliters of whey drink three times a week,
2. consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
3. consumption of 400 milligrams of vitamin E three times a week,
4. control group: no intervention. Patients were followed for 2 months. At the beginning and the end of the 2-month intervention period, 10 milliliters of blood were taken from all of the patients and nutritional status of the patients were assessed as the primary outcome. Serum levels of malondialdehyde, c-reactive protein, albumin, transferrin and lipoproteins were also measured. SGA, MIS and SF-12 questionnaires were filled for all of the patients at the beginning and the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

whey drink fortified with vitaminE

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

Group Type EXPERIMENTAL

whey drink fortified with vitaminE

Intervention Type DIETARY_SUPPLEMENT

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

vitaminE

consumption of 400 milligrams of vitamin E three times a week,

Group Type EXPERIMENTAL

vitamin E

Intervention Type DIETARY_SUPPLEMENT

consumption of 400 milligrams of vitamin E three times a week,

D- control

control group: no intervention,

Group Type NO_INTERVENTION

No interventions assigned to this group

whey drink

consumption of 220 milliliters of whey drink three times a week,

Group Type EXPERIMENTAL

whey drink,

Intervention Type DIETARY_SUPPLEMENT

consumption of 220 milliliters of whey drink three times a week,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

whey drink,

consumption of 220 milliliters of whey drink three times a week,

Intervention Type DIETARY_SUPPLEMENT

whey drink fortified with vitaminE

consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

Intervention Type DIETARY_SUPPLEMENT

vitamin E

consumption of 400 milligrams of vitamin E three times a week,

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* mean age of 17-65 years old;
* having mild, moderate or severe malnutrition based on the SGA (subjective global assessment) assessment;
* be dialyzed at least 2 times a week for 3 months

Exclusion Criteria

* hospitalization in the last month;
* active infection;
* using immunosuppressant drugs or multi-vitamins;
* pregnancy, consuming whey or soy products
Minimum Eligible Age

17 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shiraz University of Medical Sciences

OTHER

Sponsor Role collaborator

Mohammad Hassan Eftekhari

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohammad Hassan Eftekhari

professor. PhD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohammad Hassan Eftekhari, professor

Role: STUDY_DIRECTOR

Shiraz University of Medical Sciences

References

Explore related publications, articles, or registry entries linked to this study.

Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2.

Reference Type DERIVED
PMID: 32390133 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

91-6424

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Soy Protein in Early Diabetic Nephropathy
NCT00067678 COMPLETED PHASE1/PHASE2